Bugworks Research Inc.

Celebrating a decade of innovation-driven research to address two major health issues afflicting humanity - #antimicrobialresistance and #cancer. Bugworks is delighted to present a visual capsule of our journey thus far. https://lnkd.in/duEiCizG #amr #drugresistance #superbugs #drugdiscovery #drugdevelopment #innovation #cancer #immunooncology #tumourmicroenvironment #affordability #accessibility #translationalresearch #healthcare

We are delighted that #Bugworks was featured in a story published by the #BBC titled “India's 'blockbuster' drugs to take on deadly superbugs”.   Link - https://lnkd.in/g7Ts2E_s   This article features the research being carried out at Bugworks and a quote from our CEO Anand Anandkumar.   A 30-member Bengaluru-based biopharma firm Bugworks Research has partnered with Geneva-based non-profit Global Antibiotic Research and Development Partnership, or GARDP, to develop a new class of antibiotics for treating serious drug-resistant infections. Currently in early Phase-1 trials, the drug is five-to-eight years from market readiness. "Antibiotics are becoming less effective, but big money is in drugs for cancer, diabetes and other conditions, not antibiotics," Anand Anandkumar, CEO of Bugworks, told the BBC. "There's little innovation because antibiotics are kept as a last-resort option. Big pharma isn't focusing on antibiotic resistance. We've been funded by different organisations, but less than 10% of our funding comes from India."   This article also features other AMR innovations from India: Enmetazobactam, developed by Chennai-based Orchid Pharma, is the first antimicrobial invented in India to be approved by the US Food and Drug Administration (FDA). This injectable drug treats severe conditions like urinary tract infections (UTIs), pneumonia and bloodstream infections by targeting bacteria’s defence mechanisms rather than the bacteria itself.   Mumbai-based Wockhardt is testing a new antibiotic, called Zaynich, for severe drug-resistant infections. Developed over 25 years, the drug is currently in Phase-3 trials and expected to launch next year. Also in Phase-3 testing is Wockhardt's Nafithromycin, trademarked as MIQNAF, a three-day oral treatment for community-acquired bacterial pneumonia with a 97% success rate. Existing treatments to the disease have resistance as high as 60%. Its trials are set to conclude next year and once it's approved, the company says it could be launched commercially by late next year.   #AMR #antibioticresistance #antimicrobialresistance #superbugs #drugresistance #antibiotics #GARDP #globalhealth #infections #wockhardt #orchidpharma #ccamp  

We are delighted that our CEO Dr Anand Anandkumar will be attending the  “Fourth Global High-level Ministerial Conference on Antimicrobial Resistance” on 14 November in Jeddah, Saudi Arabia. He will be sharing his insights in the panel discussion titled: “The Road to Affordable & Quality Antimicrobials – Lessons Learnt from COVID-19 & What Next?”   #Bugworks #Research #UNGA #WHO #AMR #antimicrobialresistance #Superbugs #Globalhealth #Antimicrobials #Affordablehealthcare #Equitableaccess https://lnkd.in/gAvhD_sx

Bugworks is a proud partner among 49 global organisations to support the Supporting Innovative Global Health Technologies (SIGHT) Act, a legislation to empower the United States Agency for International Development (USAID) to boost its R&D capabilities for health care technologies in low and middle income countries (LMICs) abroad.    This legislation was introduced by U.S. Senator Cory Booker (D-NJ), Chair of the Africa and Global Health Policy Subcommittee last November and co-led by U.S. Representatives Brian Fitzpatrick (D-PA-01), Maria Salazar (R-FL-27) and Chrissy Houlahan (D-PA-06) last November.   "With its extensive presence in LMICs and its strong track record of fostering public-private partnerships, USAID is uniquely positioned to drive groundbreaking health innovation. It is encouraging to see congressional leaders in both the House and Senate recognize USAID's potential to embrace new disease-agnostic program areas that will complement the ongoing USAID R&D partnerships that have already been instrumental in saving millions of lives around the world."    "We applaud Senator Booker for his leadership in advancing next-generation health innovations that are critical for tackling both known and emerging global health challenges by expanding the global health R&D ecosystem within the US government," said Dr. Kristie Mikus, Executive Director of the Global Health Technologies Coalition (GHTC), which represents 49 nonprofit organizations, academic institutions, and aligned businesses dedicated to advancing life-saving innovations globally.   The full text to this announcement can be accessed at: https://lnkd.in/eVqRyNgP   #Bugworks #USAID #globalhealth #LMICs #researchanddevelopment #innovation #partnerships #collaboration #USCongress #technologies

We are pleased to announce that our Senior Vice President, Vasan Sambandamurthy, has received an invitation to speak at the Manipal Centre for Biotherapeutics Research (MCBR).  Vasan Sambandamurthy will present insights on the topic "The Science Behind the Development of Life-Saving Biotherapeutics," contributing to the advancement of research and innovation in biotherapeutics. Additionally, he has been invited to deliver a guest lecture on "A Six-Decade Wait for a Novel Broad-Spectrum Antibiotic: Discovery and Development of BWC0977" at KMC, Manipal, in collaboration with MCBR. This invitation underscores our steadfast commitment to fostering collaborations with esteemed institutions and professionals in the field. #AMR #Antimicrobialresistance #Bugworks #MCBR #KMC #Guestlecture #keynote

We are delighted that our co-founder and CEO, Anand Anandkumar, will participate as a panellist at the World Health Summit 2024 in Berlin. He will participate in the “GHL 05—Ensuring Equitable Access to Antibiotic Treatments” session hosted by Dr. Peter Beyer from the Global Antibiotic R&D Partnership (GARDP). Dr Thomas Breuer (GSK), Dr Hebah Dada (PHA, Saudi Arabia), Dr Rhonda Sealy-Thomas (PAHO/WHO), and Dr Sara Tomczyk (Robert Koch Institute) will join him as co-speakers. This year’s World Health Summit will focus on the theme Building Trust for a Healthier World.  This unique international strategic forum for global health brings together stakeholders from politics, science, the private sector, and civil society from around the world to set the agenda for a healthier future by inspiring innovative solutions for better health and well-being for all.   Link : https://lnkd.in/ek3WDQ-d   #amr #drugresistance #antimicrobialresistance #globalhealth #mdr #superbugs #bugworks

Our CEO Anand Anandkumar spoke at the sidelines of the #UNGA event last week in New York on how small and medium enterprises #SME are spearheading the global challenge of developing new drugs against “superbugs”. He also shared key points on - Continued challenges in biotech funding – “Science is difficult and business model of antibiotics is even more difficult”.   - The broken business model leading to several biotech companies going bankrupt, despite getting marketing approval for a new drug. - Need for investment in innovative science coming from LMICs and support the entire discovery and development phases of antibiotics to tackle the rising tide of AMR. - Innovating in India for the globe – LMICs bear the biggest brunt of AMR and demonstrating activity of new molecules against “superbugs” from here provides rigour and evidence to take these assets into clinical development and launch across the world. - He also emphasised on the need for innovative and contextualised solutions coming out of LMICs. He alluded to the fact that new solutions can come out of India and the “Go to Globe” strategy will ensure that innovation is available everywhere, especially in LMICs where the need is high. - The importance of building global partnerships to enable affordable access to life-saving drugs wherever the need and patient is in contrast to the prevailing model of approval and launch in the Western markets and these drugs reaching LMICs after 10-15 years. - He thanked not-for-profit entities like CARB-X and GARDP to support innovation in the AMR space and creating access pathways in LMICs. The full interview can be accessed at the following link: https://lnkd.in/gsdJgv5D   #UNGA79 #WHO #worldhealthorganisation #antibiotics #drugresistance #CARBX #GARDP #AMR #bugworks #superbugs #innovation #sme #pushandpullincentives

  We at Bugworks Research Inc. are proud that our co-founder and CEO, Anand Anandkumar, has the unique honour of representing as a biotech innovator at the world governments meet at the United Nations General Assembly (UNGA) in New York. He will participate in an all-important discussion on formulating a new global declaration on the fight against antimicrobial resistance.    #WHO #UNGA79 #UNGA #GlobalHealth #AMR #antimicrobialresistance #Bugworks #SME

We are delighted that our co-founder and CEO, Dr Anand Anandkumar, will be at the United Nations General Assembly (UNGA 79) high-level meetings on antimicrobial resistance (AMR). He will be participating in a panel discussion on the theme “Investing in the present and securing our future together: accelerating multisectoral global, regional and national actions to address antimicrobial resistance, " held at the United Nations Headquarters in New York on 26 September 2024. At this global event, Anand will be sharing his perspectives on AMR and how India can be a solution provider to the world of AMR.  Know more : https://lnkd.in/dA7-QK65. #UNGA79 #UNGA #AMR #GlobalHealth #WHO #Bugworks #antimicrobialresistance

We are pleased to announce the recent publication of our clinical antibacterial asset in Nature Communications! Our study introduces BWC0977, a Novel Bacterial Topoisomerase Inhibitor (NBTI) with promising potential for combating multi-drug-resistant (MDR) pathogens. It demonstrates efficacy against a wide range of MDR Gram-negative and Gram-positive bacteria, including fluoroquinolone, carbapenem, and colistin-resistant strains. It has been proven to be safe and well-tolerated in early-phase clinical trials. This breakthrough positions BWC0977 as a potential solution for treating critical-care infections, including MDR bacterial pneumonia. Read the full paper here: https://lnkd.in/gH5iG5XQ #AntimicrobialResistance #PharmaInnovation #innovation #MDR #AMR #ScientificBreakthrough #NatureCommunications #Research